[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mtap-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MTAP Gene",29,23,[8,16,23,30,36,43,49,56,62,68,74,80,86,92,98,104,110,116,122,128,134,140,146,152,159,166,172,178,184],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06630416","Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors",[12],"Phase 2","RECRUITING","2026-08-26T02:15:00.557154Z","2026-07-05T05:32:16.766648Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06130553","A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced\u002FMetastatic Solid Tumors",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.744919Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07601243","Study of GS-2426 in Participants With Advanced Solid Tumors",[27],"Phase 1","2026-08-26T02:17:15.156099Z","2026-07-05T03:45:20.254014Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06414460","Study of ISM3412 in Participants With Locally Advanced\u002FMetastatic Solid Tumors",[20],"2026-08-26T02:16:47.762107Z","2026-06-18T12:24:03.105083Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT07063745","A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion",[40],"Phase 2\u002FPhase 3","2026-08-26T02:15:46.655893Z","2026-05-05T02:43:29.496539Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT07283705","A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer",[12],"2026-08-26T02:17:00.709807Z","2026-05-05T02:43:29.390394Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":54,"content_modified":55},"NCT06883747","Clinical Trial of BMS-986504 in Recurrent GBM Patients",[53],"Early Phase 1","2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.182773Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06623110","Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.883549Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT06855771","A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)",[12],"2026-08-26T02:19:21.761002Z","2026-05-05T02:43:28.733864Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06589596","An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:28.661301Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT07549022","Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor",[20],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:28.649683Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06922591","Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients",[20],"2026-08-26T02:18:56.409949Z","2026-05-05T02:43:27.806278Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT07485049","Phase 0\u002F2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors",[53],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:27.588793Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT07128303","Study of GS-5319 in Adults With Solid Tumors",[27],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:27.244763Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06914128","A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors",[20],"2026-08-26T02:19:08.862440Z","2026-07-05T05:32:16.701684Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT06137144","AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.",[20],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.704937Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07382544","Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss",[27],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:26.931101Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06810544","Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss",[20],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.714299Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[27],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07492680","A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and\u002For Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",[12],"2026-08-26T02:17:47.813245Z","2026-06-16T05:54:07.939792Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07594626","BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion",[20],"2026-08-26T02:17:39.048487Z","2026-05-29T15:36:40.204907Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT05732831","Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.947953Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT05245500","Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion",[27],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:26.709142Z",{"nct_id":153,"title":154,"phases":155,"status":156,"updated_at":157,"content_modified":158},"NCT07579221","Ph1\u002F2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer",[20],"NOT_YET_RECRUITING","2026-08-26T02:17:32.059863Z","2026-05-13T02:55:06.783026Z",{"nct_id":160,"title":161,"phases":162,"status":163,"updated_at":164,"content_modified":165},"NCT06333951","Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T02:10:37.231905Z","2026-05-05T02:43:28.648624Z",{"nct_id":167,"title":168,"phases":169,"status":163,"updated_at":170,"content_modified":171},"NCT06593522","A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)",[12],"2026-08-03T03:02:58.488119Z","2026-05-05T02:43:27.926357Z",{"nct_id":173,"title":174,"phases":175,"status":163,"updated_at":176,"content_modified":177},"NCT07076121","A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)",[40],"2026-08-03T03:03:50.544633Z","2026-05-05T02:43:27.514544Z",{"nct_id":179,"title":180,"phases":181,"status":163,"updated_at":182,"content_modified":183},"NCT06360354","A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)",[27],"2026-08-03T03:26:30.254593Z","2026-05-05T02:43:29.347634Z",{"nct_id":185,"title":186,"phases":187,"status":163,"updated_at":188,"content_modified":189},"NCT06188702","S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP",[20],"2026-08-03T03:02:32.170340Z","2026-05-05T02:43:28.020362Z"]